Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Rhea-AI Summary
Polyrizon (Nasdaq: PLRZ) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on March 25, 2026.
The report is available on the SEC website and Polyrizon’s investor relations site; shareholders may request a free copy from Investor Relations at IR@polyrizon-biotech.com.
Positive
- None.
Negative
- None.
News Market Reaction – PLRZ
In the Mar 26 session, PLRZ declined 3.37%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Acquisition MOU | Neutral | -5.0% | Non-binding MOU to acquire up to 20% of Colugo for up to $6M. |
| Mar 17 | Clinical trial prep | Positive | -4.2% | Agreement with global preclinical CRO for GLP biocompatibility studies. |
| Mar 10 | GMP manufacturing | Positive | -0.1% | Successful GMP batch of CTM supporting planned U.S. clinical study. |
| Feb 26 | Preclinical data | Positive | +1.1% | Naloxone formulation showed improved nasal deposition vs. reference product. |
| Feb 17 | Product branding | Positive | +0.4% | Unveiling NASARIX™ brand and outlining planned clinical timeline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive development and trial updates often saw mixed reactions, with several declines following constructive news.
Over the past months, Polyrizon announced multiple development milestones, including GMP manufacturing support for a planned U.S. clinical study (Mar 10, 2026) and a preclinical CRO agreement for GLP studies (Mar 17, 2026). It also reported favorable naloxone deposition data and branded its lead NASARIX™ product. An acquisition MOU for up to a 20% stake in Colugo for up to $6,000,000 preceded today’s Form 20-F filing, which formalizes 2025 financials and risk disclosures.
Key Terms
form 20-f regulatory
u.s. securities and exchange commission regulatory
nasdaq financial
pre-clinical-stage medical
intranasal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC").
The report is available on the SEC's website, at www.sec.gov and Polyrizon’s Investor Relations website, at https://investor.polyrizon-biotech.com/.
Shareholders can obtain copies of Polyrizon’s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon’s Investor Relations Department at IR@polyrizon-biotech.com.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 24, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
